<DOC>
	<DOCNO>NCT00401817</DOCNO>
	<brief_summary>Primary Objective 1 . To evaluate safety profile Bevacizumab ( Bevacizumab™ ) - Rituximab ( Rituxan® ) -CHOP ( RA-CHOP ) patient newly diagnose mantle cell lymphoma ( MCL ) . Secondary Objectives 1 . To evaluate response rate time disease progression RA-CHOP regimen patient newly diagnose MCL . 2 . To prospectively characterize angiogenic profile MCL patient RA-CHOP treatment .</brief_summary>
	<brief_title>Bevacizumab + CHOP-Rituximab Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>Bevacizumab administer 15 mg/kg day 1 6 cycle Rituximab administer 375 mg/m2 day 3 6 cycle ( usual premedications ) Standard CHOP chemotherapy administer day 3 every 21 day ( full dose ) 6 cycle treatment Once complete six cycle therapy ( ~18 week ) , patient evaluate every 3 month first year post treatment , every 6 month disease progression death year 2 5 post treatment . Patients disease progression contact every 6 month death ass survival status .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm diagnosis mantle cell NonHodgkin 's Lymphoma characteristic immunophenotypic profile : CD5 ( + ) , CD19 ( + ) CD20 ( + ) , cyclin D1 ( + ) , CD23 ( ) CD10 ( ) Patient receive prior anticancer therapy lymphoma Laboratory parameter ( unless consider investigator due lymphoma ) : Absolute neutrophil count &gt; 1000 cells/mm3 Platelet count &gt; 50,000 cells/mm3 Hemoglobin &gt; 7 gm/dL Creatinine &lt; 2.0 x ULN Total bilirubin &lt; 2.0 x ULN Patient least one tumor mass &gt; 1.5 cm one dimension Available tumor tissue correlative study ( rebiopsy perform need ) Patient &gt; 18 year old Patient KPS &gt; 50 % Patient sign IRBapproved inform consent Patient agree use birth control duration study Known central nervous system ( CNS ) involvement lymphoma Known hepatitis infection Known HIV positivity Known history renal disease proteinuria ; urine protein : creatinine ratio ³1.0 screening Uncontrolled hypertension : blood pressure &gt; 150/100 mmHg screen Unstable angina History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease New York Heart Association ( NYHA ) Grade II great congestive heart failure Patient ejection fraction &lt; 50 % Patient take coumadin , know history thrombosis within last 6 month Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 1 History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 1 Serious , nonhealing wound , ulcer , bone fracture Concomitant malignancies previous malignancy within last five year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . Patient pregnant nursing Patient receive investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>